Hoffmann K J, Regårdh C G, Aurell M, Ervik M, Jordö L
Clin Pharmacokinet. 1980 Mar-Apr;5(2):181-91. doi: 10.2165/00003088-198005020-00005.
Plasma concentration and urinary excretion of total and 2 active metabolites of metoprolol have been studied in patients with varying degrees of renal impairment and in healthy subjects after intravenous and oral administration of 20 and 50 mg of 3H-metoprolol tartrate respectively. Renal clearance of total metabolites correlated directly with 51Cr-EDTA clearance (r = 0.95, p less than 0.001). A reduction of glomerular filtration rate (GFR) by 70 to 80% increased the elimination half-life of total metabolites and of the active metabolite alpha-hydroxymetoprolol about 3-fold. Significant accumulation was, however, only observed in the patients with a GFR of about 5 ml/min. Even in these patients, the contribution of alpha-hydroxymetoprolol to the beta-adrenoceptor blocking effect of metoprolol will be negligible. The second active metabolite studied is eliminated via biotransformation, and the urinary excretion as well as the plasma concentration of this metabolite were extremely low in comparison with those of the parent drug.
分别对20毫克和50毫克的3H-酒石酸美托洛尔进行静脉注射和口服给药后,在不同程度肾功能损害患者及健康受试者中研究了美托洛尔的总血浆浓度以及两种活性代谢物的尿排泄情况。总代谢物的肾清除率与51Cr-EDTA清除率直接相关(r = 0.95,p < 0.001)。肾小球滤过率(GFR)降低70%至80%会使总代谢物及活性代谢物α-羟基美托洛尔的消除半衰期增加约3倍。然而,仅在GFR约为5毫升/分钟的患者中观察到明显蓄积。即便在这些患者中,α-羟基美托洛尔对美托洛尔β-肾上腺素能受体阻断作用的贡献也可忽略不计。所研究的第二种活性代谢物通过生物转化消除,与母体药物相比,该代谢物的尿排泄量及血浆浓度极低。